4.8 Article

Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells

Journal

SCIENCE
Volume 367, Issue 6478, Pages 642-+

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aay5516

Keywords

-

Funding

  1. Cancer Council of Victoria [1126866]
  2. Australian Research Council (ARC) [CE140100011, DP170102471]
  3. National Health and Medical Research Council of Australia (NHMRC) [1165467, 1113293]
  4. Victorian Government, Australia
  5. ARC Future Fellowship [FT140100278]
  6. Department of Health and Human Services acting through the Victorian Cancer Agency
  7. NHMRC Senior Principal Research Fellowship [1117766]
  8. Deutsche Forschungsgemeinschaft [GRK2168]
  9. University of Melbourne through the International Research and Research Training Fund
  10. NHMRC Principal Research Fellowship [1154502]
  11. ARC Discovery Early Career Researcher Award [DE170100575]
  12. AMP Tomorrow Fund
  13. National Health and Medical Research Council of Australia [1154502, 1165467] Funding Source: NHMRC
  14. Australian Research Council [DE170100575] Funding Source: Australian Research Council

Ask authors/readers for more resources

Gamma delta (gamma delta) T cells are essential to protective immunity. In humans, most gamma delta T cells express V gamma 9V delta 2(+) T cell receptors (TCRs) that respond to phosphoantigens (pAgs) produced by cellular pathogens and overexpressed by cancers. However, the molecular targets recognized by these gamma delta TCRs are unknown. Here, we identify butyrophilin 2A1 (BTN2A1) as a key ligand that binds to the V gamma 9(+) TCR gamma chain. BTN2A1 associates with another butyrophilin, BTN3A1, and these act together to initiate responses to pAg. Furthermore, binding of a second ligand, possibly BTN3A1, to a separate TCR domain incorporating V delta 2 is also required. This distinctive mode of Ag-dependent T cell activation advances our understanding of diseases involving pAg recognition and creates opportunities for the development of gamma delta T cell-based immunotherapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available